The Gross Law Firm Reminds ESSA Pharma Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 – EPIX

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of ESSA Pharma Inc. regarding a class action lawsuit due to alleged misleading statements related to the efficacy of masofaniten in combination with enzalutamide for prostate cancer treatment [1][3]. Summary by Sections Class Action Details - The class period for the lawsuit is from December 12, 2023, to October 31, 2024 [3]. - Allegations include that the defendants made materially false statements about masofaniten's efficacy and overstated its clinical and commercial prospects [3]. Allegations Against ESSA Pharma Inc. - The complaint claims that masofaniten in combination with enzalutamide showed no clear efficacy benefit over enzalutamide alone [3]. - It is alleged that the M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint [3]. - The defendants are accused of misleading investors about the treatment's effectiveness for prostate cancer [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by March 25, 2025, to participate in potential recovery [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].